Women with type 1 von Willebrand disease (VWD) or low VWF levels face distinct haemostatic challenges in the postpartum period. This protocol defines the recommended approach for this specific population based on current clinical evidence.
Female patient with type 1 von Willebrand disease or low VWF levels, during the postpartum period. This window carries elevated bleeding risk and calls for proactive, evidence-informed management.
Guidelines conditionally recommend a systemic antifibrinolytic agent in postpartum women with type 1 VWD or low VWF levels. The complete regimen — including route, dosing schedule, and duration criteria — is available in the full protocol.
Full dosing details, clinical decision points, and supporting evidence are behind the link below.
DOI: 10.1182/bloodadvances.2020003264.
The guideline panel suggests the use of tranexamic acid over not using it in women with type 1 VWD or low VWF levels (and this may also apply to types 2 and 3 VWD) during the postpartum period (conditional recommendation based on low certainty in the evidence of effects).
Tranexamic acid may be given systemically via the oral or IV route. The oral dose is 25mg/kg (typically 1000-1300 mg) 3 times per day for 10 to 14 days or longer if blood loss remains heavy.
View source ↗